Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the toothless meth addicted ones
im long on ATAO, 10m shares only added to OS in 3 months is minimal as it get, lithium with SXOOF 60% interest connections
Yup! Dirty strippers
nice to hear from you buddy, markets play like a dirty sanchez
so many red candles, new symbol same stock
https://www.stockscores.com/chart.asp?TickerSymbol=%20ziop&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
so many red candles, new symbol same stock
https://www.stockscores.com/chart.asp?TickerSymbol=%20ziop&TimeRange=365&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=AccDist&Indicator2=StochRSI&Indicator3=CMF&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
NEW TICKER SYMBOL.........just yesterday they announced re-brand , and moving to texas.....trials M D ANDERSON
sounds like a buy-out announcement is in the near future
$$$$$$$$$$$$ ALAUNOS $$$$$$$$$$$$$$$$$...gl
Re: Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics
New symbol
TCRT
effective tomorrow at open
have not been in this for a while......dropped off a cliff with about 5 mins left.......bought a pretty good pile of 94`s and 95`s
insider buying in the fourth qtr.
$$$$$$$$$$$$$$$$$$$ ZIOPHARM $$$$$$$$$$$$$$$....gla
hu hi @dirty ,confirm completly, chart 2010 simply to read. Always same procedure. Insiders bougt shares- in Bottom 1,60 - but not sure abt next target to sell? May you look to NXO.v just startin with their new optical patents. ZiOP long term Chart is periodical up to 2,25 - 2,90 - 3,73 - so far re charting.
Last - 5 Insiders bought shares inSeptember. SEC Filings. Anyone idea right point to sell ? Hold several stocks in CAD and US. HD.
agree on 10 bagger......been buggin me on high price!........just checked a trading log from 2015.......i see flipping this a lot in the $12-$14 range back then
$$$$$$$$$$$$$$$$$$$$ ZIOPHARM $$$$$$$$$$$$$$$$$$$$$$
used to ..buy sell short and cover this many times daily back about 2016...2017......still have a core thats about 3 years old......good to see this moving again...played it alot when it was trading about $7....mgmt from Xon f`d this up for a while.....and kirk took out quite a bit of its value
he`s long gone......time for ZIOPHARM to shine once again...gla
$$$$$$$$$$$$$$$$$$$$ ZIOP $$$$$$$$$$$$$$$$$$$$
A great trading day for a smart company with nimble trades and keep a piece in your pocket for the long term break out play. 10 bagger in the making
If the market can pull its shit together this will do real well tomorrow
Hope you are still enjoying this as much as i am. Check out RGLS also, good data so far and end of Q1 should be lift off!
Blackrock increased ownership
Oncology stocks are on the move my picks are:
1.ZIOP 800 million market cap chart looks good. Gene editing play.
2.PDSB 60 million market cap chart looks great CD8+ (killer) T-cells.
$ZIOP
Company managed to successfully convince one of the large investors to change their nay vote. All items passed with the exception of the issuance of additional shares. Apparently the concession for changing their vote was to make the point the company must produce before they get access to any additional funds. No more dilutive financing without results. Minor victory, but largely disappointed.
It appears that the Company does not have the shareholder votes to re-elect the Board of Directors nor approve the ridiculous compensation management is getting. We will know tomorrow (if not postponed). I hope all proposals fail. Cooper is not CEO material, not even senior manager level of any kind. Never invest in a biotech with an MD at the helm, never; no matter how promising. So many clinical deadlines have passed, so many promises broken, no urgency to get things done; no fiduciary sense of any kind, no shareholder accountability. All this without a modicum of explanation of any kind to the shareholders. The ridiculous secondary of four months ago was the last straw, literally conceding to shorts by allowing them to `invest' and cover. . . . the same people who have tried to bankrupt this company for the last five years.
The company may take a $$ hit on this but will ultimately be placed in more competent hands; we can not get any worse decision making than present. We have no idea after five years of what, if any, of this `ground breaking' technology clinically works. Clearly there are issues with the NCI. Programs invested in five years ago just drop off the company radar with no comment by management. Worst company I have ever encountered. Millions of bonuses and compensation to Cooper over the years and he has not once bought a single share in this company; just the recipient of endless gifts. Complete disgrace. Don't want him as CMO either. Carl June to the rescue please.
Clearly Cooper deserves another bonus, talent like his is hard to come by.
5 years as CEO - nothing accomplished/achieved. Everything delayed yet again; this time, saved by the virus. First three years was the conflict with Kirk. First dosing of a patient rumored to be any decade now.
Just one shot left on goal now from three decent shots outlined five years ago. Any hope now is placed solely on Rosenberg. No longer an investment, merely one roll of the roulette ball. Technology of numerous other biotechs have caught and surpassed us, this is merely a management ATM. Cooper has not bought one share in this company from his own funds.
Wow earning estimates met for this quarter - (21q1)
quiet board....where is everyone....earnings miss, as expected....now at $2.82....this might get interesting soon...glta
waiting patiently for this to drop under $3 for a bounce play.....in and out quickly!.....4 or 5 years ago, this was the "perfect kiddy coaster"...…..buy sell short cover...dozen times a day...….predictable time frames......made truckloads on this......too bad their science didn`t keep up with their competition...…..O S should be well over 225 when this round of dilution ends.....ziop will be otc next year....glta
* * $ZIOP Video Chart 02-10-2020 * *
Link to Video - click here to watch the technical chart video
Thanks
I will check out.
Good move, keep watching. $2's are very possible. Another secondary to dilute shareholders. No progress in last five years. Clinical trial pulled with no management comment. Secondary issued with no management comments. Only one remaining "shot" on goal. Rosenberg NCI trial has still not dosed its first patient. IL-12 looks like a bust after being a primary strategy for years. Other Bio companies making great strides; our heralded Sleeping Beauty delivery system on the verge of being completely antiquated as CEO bumbles around letting timeline after timeline slip. Terrible CEO and probably not CMO caliber either (despite being a self proclaimed genius). Lawrence had MDA roots, I bet they do not miss him.
Still hope for share price improvement of course, but buying it as a lottery ticket should be your financial objective. PROF and AUPH are just two of dozens of better investments if you are looking for clinical stage or recently FDA approved companies. Was a bull on this company for years, now just a bag holder on my remaining few shares.
Thanks for your thought. I appreciate that. I have been just watching for 2 months, thinking to buy some when time is right. I have a lot of patience. Let me know if you think it is good time to get in this stock.
it closed the day at $3.40...right on the line of lin /reg50.....big vol,but I expect this to dive some more tomorrow......their "sleeping beauty platform" was hot for a couple years, but another company under the XON umbrella had a better car-t program...….been quiet this last year, however, you don`t get in to M D Anderson, without something under the hood....if they remain quiet, this could slide under $2 again.....this one is a tough call....good luck if you jump in !....I`m gonna watch the dilution for a week and then think about it again....with wrnts and offering....O S could easily be 225 mill or so...….too high for a small bio without revenue..gl
* * $ZIOP Video Chart 02-05-2020 * *
Link to Video - click here to watch the technical chart video
They are trading already. How is it IPO now? I need to be educated.
been trading this for years......havn`t been in it for quite a while......stuck in the 4-5 $ channel.....this new offering puts them well over 200mill O S...….they need to come out with some "killer news" from M D Anderson......otherwise this will head back down towards a buck.....$1.50 low about a year ago.....I see big R/S in march....CAUTION!!!...glta
We know about the product, they are going to target more neoantigens, working on 'next gen' versions (likely multiplex editing) [1], addressing manufacturing and should have dosed the first patient. If you have info on all this when it comes to ZIOP then do share it.
Ref:
1 (data from CRSP) https://crisprtx.gcs-web.com/static-files/8ea0746a-7aaf-4350-a451-db66efa26f6b
I think a better video is Demystifying Medicine. At around the 53 minute mark Dr. Rosenberg says the reason why vaccines have failed is because they don't generate enough T-cells to impact the cancer and you can't get rid of enough Tregs, MDSCs and M2 macrophages. Also, (in my view) he forgot about targets [1].
To address the first problem GRTS is using a heterologous prime-boost vaccine. Preclinical data show this not only induces a T-cell response which is comparable to different adoptive cell transfer treatments, but also the cells persist longer [2]. The early human data (more will likely be presented at AACR and ASCO) are pretty encouraging [3].
The second can be dealt with via mAbs and/or small molecules (that deplete and/or reprogramme) which are in development.
As for the third the company tested its selection platform (which they continue to improve) against public methods and looked at how both compared to the tandem minigene approach used by Dr. Rosenberg/US NCI [4]. For the top twenty MHC Class I restricted neoantigens we know the majority (19/26, 73%) would be included vs. only 9/26 (35%) with public tools. Sometime this year they plan to incorporate MHC Class II restricted neoantigens in their vaccines as the dataset and model for these targets will be sufficiently robust. This should improve the efficacy [5] and will try to prioritise clonal neoantigens [6].
In addition, they have a deal with BLUE [7].
Refs:
1 https://videocast.nih.gov/summary.asp?Live=30267&bhcp=1
2 https://cancerres.aacrjournals.org/content/78/13_Supplement/724
3 https://www.fiercebiotech.com/biotech/gritstone-posts-one-most-potent-immunogenic-responses-for-a-neoantigen-vaccine
4 https://www.nature.com/articles/nbt.4313
5 https://www.nature.com/articles/s41586-019-1671-8
6 https://science.sciencemag.org/content/351/6280/1463
7 https://www.businesswire.com/news/home/20180823005039/en/bluebird-bio-Gritstone-Oncology-Announce-Strategic-Collaboration
I'm not giving any advice nor do I have a (short) position in this company and don't plan to initiate one anytime soon.
So your view is short ZIOP
Buy Gritstone, Gilead, Sangamo
Ok, got it
Ok, got it!
u think PACT pharma is ahead, cool
Watch this in full
Rosenberg addresses Cancer Vaccines during Q&A
Then later while he is in the audience... Rosenberg questions Nishimura + Panel
https://videocast.nih.gov/summary.asp?live=29065&bhcp=1
He said they had to make some amendments to the IND and by now should have dosed the first patient. With the money they will open a GMP manufacturing facility in South San Francisco sometime this year to support the end-to-end production, supply chain and leverage the in-house manufacturing facility to automate manufacturing and analytical processes to reduce cycle time and manufacturing cost.
This is very likely GILD's (under CRADA) https://clinicaltrials.gov/ct2/show/NCT03412877
Last year SGMO got an upfront payment of $150M from GILD and are eligible to receive up to $3.01B in potential milestones. They are working together on a program that creates both viral and non-viral methods to disrupt and insert certain genes into T and NK cells (both autologous and allogeneic (from healthy donors and induced pluripotent stem cells)), including the insertion of genes that encode CARs, TCRs and NKRs directed to up to ten mutually agreed targets. GILD is responsible for all clinical development costs and the commercialisation of any resulting approved product(s).
The first allogeneic product (from healthy donors) is an anti-CD19 CAR-T and a PhI trial should be open in 2H. The second is another allogeneic (again, from healthy donors) CAR-T targeting CD-19/20 (using a bicistronic vector, which allows for the expression of two different CARs on the same cell). It will use Hu19 [1], but I don't know when a PhI is going to start. A third product (unknown) is now moving forward. Based on this I would be surprised if a fourth wasn't in the works.
Once the neoantigen reactive TCR-T trial has more data they could move forward with others as GILD have their own method to screen patient TCRs for reactivity [2] and therefore don't need to rely on a tandem minigene library used by Dr. Rosenberg/US NCI. However, patients could lack T-cells with an adequate affinity due to TCR and other editing. To overcome such limitations, tumour-specific TCRs harvested from healthy donors could be used instead (they are likely working on this) [3].
Also, with synNotch T (and NK) cells can be engineered to locally produce a range of payloads, including pro-inflammatory cytokines and checkpoint antibodies. Given the flexibility of this, it should be possible for the cells to produce many, 'customised' for different cancer types. Some might act in concert with T or NK cell killing and others might act independently to remodel the immunosuppressive TME and engage the host immune system. Significantly, localised production should avoid the toxicities observed with systemic delivery and reduce costs [4].
In addition, the (CAR)NK cells could be used in patients whose cancer has become resistant to T-cell [5-7]. Data from another group shows activity [8].
Refs:
1 https://ashpublications.org/blood/article/132/Supplement%201/697/266071/Low-Levels-of-Neurologic-Toxicity-with-Retained
2 https://www.nature.com/articles/nm.3359
3 https://science.sciencemag.org/content/352/6291/1337
4 https://www.cell.com/fulltext/S0092-8674(16)31244-2
5 https://www.cell.com/cell/fulltext/S0092-8674(17)30065-X
6 https://www.sciencedirect.com/science/article/pii/S2211124719310502
7 http://jem.rupress.org/content/209/13/2351.long
8 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(19)30097-8
''1)
In the Nov 26th 2019 PACT Pharma video -
President/Chief Tech Tim Moore says they will go after 1 Neoantigen and potentially as much as THREE.... you can suggest they are doing 4 and wayyy ahead if you want... But that's simply NOT THE CASE''
In the current trial, they are targeting a single neoantigen [1], but we know from the PR they will target more. This stated four [2] and I've heard more (sources I trust).
''2)
ZIOP has a Phase 2 - you try to dismiss/downgrade that all u want.''
Again, I know this. The estimated primary completion date is Dec 31, 2028 [3].
''3)
PACT Pharma has not DOSED as of Nov 26th per Tim Moore... in fact They have had to amend their IND several times.
You act like they are way ahead and yet they too have not DOSED... their Phase 1.''
Care to cite this video and the time at which Mr. Moore stated this?
''You would do well to look up Dr Rosenberg opinion of Neon/Gritstone and his discussion with Dr Michael Nishimura''
What does he say in them?
''Good luck catching $ZIOP with your Cancer Vaccines''
ZIOP's IL-12 has failed in melanoma, breast and has yet to show any activity in rGBM. We also know that they have been 'leapfrogged' in the CAR-T space and when it comes to vaccines GRTS have presented some early data on their vaccine [4].
Refs:
1 https://clinicaltrials.gov/ct2/show/NCT03970382
2 https://www.biocentury.com/bc-extra/preclinical-news/2019-07-22/pact-makes-case-neoantigen-specific-tcrs-patient-blood
3 https://clinicaltrials.gov/ct2/show/NCT04102436
4 https://www.fiercebiotech.com/biotech/gritstone-posts-one-most-potent-immunogenic-responses-for-a-neoantigen-vaccine
Followers
|
83
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1230
|
Created
|
08/08/06
|
Type
|
Free
|
Moderators |
http://www.ziopharm.com/
http://finance.yahoo.com/q/h?s=ZIOP
ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of a portfolio of in-licensed cancer drugs. It focuses primarily on the licensing and development of proprietary drug candidate families that are related to cancer therapeutics that are already on the market or in development. The company�s product candidates include ZIO-101, ZIO-201, and ZIO-301, which are in phase I and/or II studies. ZIO-101, organic arsenic is in a phase I/II trial in patients with advanced myeloma, as well as a phase I trial in advanced cancers; ZIO-201, stabilized isophosphoramide mustard is in a phase I/II trial in patients with advanced sarcoma, as well as in a phase I trials in advanced cancers; and ZIO-301, an anti-cancer agent that targets mitosis like the taxanes is in a phase I trial. ZIOPHARM was founded in 2003 and is based in New York, New York.
>
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |